OTC · Biotechnology

Nordicus Partners Corporation (NORD) Stock Price & Fundamentals

$2.57 +2.39% OTC: NORD Healthcare

Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines.

Valuation

MetricValue
Price$2.57
Market Cap$49.97M
P/E Ratio-8.63
P/B Ratio0.73
P/S Ratio0.00
EPS (TTM)−$0.22
52-Week High$5.15
52-Week Low$1.48
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-7.95%
ROA-6.94%
ROCE-6.10%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.18

Nordicus Partners Corporation key facts

Strengths in the numbers

  • Debt/equity 0.00, below the 0.19 median across 12 Biotechnology peers (largest by market cap).

Points to check

  • Net income was negative in 3 of the last 5 fiscal years (most recently 2025).
  • Cash from operations was negative in 3 of the last 5 fiscal years.
  • Free cash flow was negative in 3 of the last 5 fiscal years.
  • Interest coverage -2598.5×: operating profit did not cover interest expense in the latest year.
  • Current ratio 0.18: current liabilities are larger than current assets.

Computed by rule from the reported figures on this page. A description of the numbers, not advice.

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACCLAcco Group Holdings Limited $2.36 -2.88% 496.15 $32.92M 0.00%
AERTAeries Technology, Inc. - Class A Ordinary Share $5.33 +1.23% 13.20 $27.97M 0.00%
FOFOHang Feng Technology Innovation Co., Ltd. $1.80 -1.10% 0.00 $13.63M 0.00%
RGPResources Connection, Inc. $2.77 +2.41% -3.23 $95.95M 7.20%
VRTXVertex Pharmaceuticals Incorporated $534.85 -0.70% 34.56 $135.60B 0.00%
REGNRegeneron Pharmaceuticals, Inc. $954.06 -0.15% 19.22 $98.68B 0.47%
MRNAModerna, Inc. $215.27 -3.63% — $87.10B 0.00%
RVMDRevolution Medicines, Inc. $168.19 -2.38% — $36.38B 0.00%

Quarterly Results — Last 8 Quarters (USD millions)

MetricSep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Sales$0$0$0$0$0$0$0$0
Operating Profit−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M
OPM-20295.8%-50612.4%——————
Net Profit−$1.0M−$2.0M−$1.0M−$1.0M−$2.0M−$1.0M$0−$2.0M
EPS−$0.10−$0.13−$0.08−$0.07−$0.08−$0.07$0.00−$0.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$0−$8.5B$0−$3.0M−$4.0M
Net Profit$0−$8.5B$0−$3.0M−$4.0M
EPS−$0.28−$1.43−$0.03−$0.32−$0.22
Op Margin——-12303.5%-58387.3%—

NORD fundamentals by fiscal year

Pick a measure to chart 10 fiscal years (2016–2025) from the company’s annual statements.

NORD revenue, fiscal 2016–2025 (USD)Revenue was $2 million in 2016 and $0 million in 2025.$0$1M$2M$3M’16’17’18’19’20’21’22’23’24’252016: $2M2017: $3M2018: $3M2019: $3M2020: $02021: $02022: $02023: $02024: $02025: $0$0

Total revenue reported for each fiscal year.

Show the numbers
Revenue (USD), by fiscal year
Fiscal year2016201720182019202020212022202320242025
Revenue$2M$3M$3M$3M$0$0$0$0$0$0
NORD net income, fiscal 2016–2025 (USD)Net income was −$1 million in 2016 and −$4 million in 2025. Below zero in 2016, 2017, 2022, 2024, 2025.−$10B−$8B−$5B−$3B$0’16’17’18’19’20’21’22’23’24’252016: −$1M2017: −$1M2018: $02019: $02020: $02021: $02022: −$8.5B2023: $02024: −$3M2025: −$4M−$4M

Net income (profit after all costs, interest and tax) for each fiscal year; a bar below the zero line is a net loss.

Show the numbers
Net income (USD), by fiscal year
Fiscal year2016201720182019202020212022202320242025
Net income−$1M−$1M$0$0$0$0−$8.5B$0−$3M−$4M
NORD operating margin, fiscal 2016–2025Operating margin was -6.2% in 2016 and 14.4% in 2019. Below zero in 2016.−10%0%10%20%30%’16’17’18’19’20’21’22’23’24’25Operating margin 2016: −6.2%Operating margin 2017: 6.2%Operating margin 2018: 22.4%Operating margin 2019: 14.4%n/a2020: no figure on filen/a2021: no figure on filen/a2022: no figure on filen/a2023: no figure on filen/a2024: no figure on filen/a2025: no figure on file14.4%

Operating profit as a percentage of revenue, by fiscal year.

Show the numbers
Operating margin (per cent), by fiscal year
Fiscal year2016201720182019202020212022202320242025
Operating margin−6.2%6.2%22.4%14.4%——————
NORD net margin, fiscal 2016–2025Net margin was -50.0% in 2016 and 0.0% in 2019. Below zero in 2016, 2017.−60%−40%−20%0%’16’17’18’19’20’21’22’23’24’25Net margin 2016: −50.0%Net margin 2017: −33.3%Net margin 2018: 0.0%Net margin 2019: 0.0%n/a2020: no figure on filen/a2021: no figure on filen/a2022: no figure on filen/a2023: no figure on filen/a2024: no figure on filen/a2025: no figure on file0.0%

Net income as a percentage of revenue, by fiscal year.

Show the numbers
Net margin (per cent), by fiscal year
Fiscal year2016201720182019202020212022202320242025
Net margin−50.0%−33.3%0.0%0.0%——————
NORD return on equity, fiscal 2016–2025Return on equity was 100.0% in 2019 and -6.3% in 2025. Below zero in 2024, 2025.−50%0%50%100%’16’17’18’19’20’21’22’23’24’25n/a2016: no figure on filen/a2017: no figure on filen/a2018: no figure on fileReturn on equity 2019: 100.0%Return on equity 2020: 100.0%Return on equity 2021: 0.0%n/a2022: no figure on fileReturn on equity 2023: 0.0%Return on equity 2024: −5.0%Return on equity 2025: −6.3%−6.3%

Net income as a percentage of shareholders’ equity, by fiscal year.

Show the numbers
Return on equity (per cent), by fiscal year
Fiscal year2016201720182019202020212022202320242025
Return on equity———100.0%100.0%0.0%—0.0%−5.0%−6.3%
NORD free cash flow, fiscal 2016–2025 (USD)Free cash flow was $0 million in 2016 and −$4 million in 2025. Below zero in 2022, 2024, 2025.−$400M−$300M−$200M−$100M$0$100M’16’17’18’19’20’21’22’23’24’252016: $02017: $02018: $02019: $3M2020: $02021: $02022: −$368M2023: $02024: −$1M2025: −$4M−$4M

Operating cash flow less capital expenditure, by fiscal year; below zero means more cash went out than came in from operations.

Show the numbers
Free cash flow (USD), by fiscal year
Fiscal year2016201720182019202020212022202320242025
Free cash flow$0$0$0$3M$0$0−$368M$0−$1M−$4M
NORD eps, fiscal 2016–2025 (USD per share)EPS was −$2.04 in 2016 and −$0.22 in 2025. Below zero in 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025.−$3−$2−$1$0’16’17’18’19’20’21’22’23’24’252016: −$2.042017: −$1.362018: −$0.182019: −$0.862020: −$0.582021: −$0.282022: −$1.432023: −$0.032024: −$0.322025: −$0.22−$0.22

Earnings per share for each fiscal year.

Show the numbers
EPS (USD per share), by fiscal year
Fiscal year2016201720182019202020212022202320242025
EPS−$2.04−$1.36−$0.18−$0.86−$0.58−$0.28−$1.43−$0.03−$0.32−$0.22

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$55.0M$2.0M$70.0M$75.0M
Total Liabilities$0$27.0M$0$10.0M$11.0M
Cash$0$7.0M$0$0$0
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0−$368.0M$0−$1.0M−$4.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$129.0M$2.0M$1.0M$0
Net Cash Flow$0−$239.0M$0$0$0
Free Cash Flow$0−$368.0M$0−$1.0M−$4.0M

Efficiency Ratios (fiscal years)

ROCE is profit before interest and tax divided by total assets less current liabilities. Payable days and the cash conversion cycle need a trade-payables line, which these statements do not carry.

Metric20212022202320242025
ROCE %—-30257.1%—-4.3%-5.4%
ROE %0.0%-30232.1%0.0%-5.0%-6.3%

Valuation & Return Ratios

MetricValue
PEG Ratio-0.23
EV / EBITDA-10.24
FCF Yield-9.32%
Quick Ratio0.18
Interest Coverage-2598.50
Return 1Y-51.94%
Return 3Y-70.56%
Return 5Y-84.30%

Ownership

Insiders Held66.92%
Institutions Held0.00%
Institutions Float Held0.00%

For Nordicus Partners Corporation, insiders hold 66.92% of the shares, institutions hold 0.00%, according to the latest holder filings.

InsiderRoleSharesLatest Transaction
GK PARTNERS APSBeneficial Owner of more than 10% of a Class of Security3,259,0202025-08-08
AC NORDIC APSBeneficial Owner of more than 10% of a Class of Security3,119,3402025-07-30
ROUF HENRIKChief Executive Officer15,9732025-08-20

Filings & documents

Nordicus Partners Corporation (NORD) reports filed with the US Securities and Exchange Commission, newest first. SEC CIK 0001011060. Links open sec.gov.

Annual reports (10-K)

Latest: 10-K for fiscal 2026 (period ended 31 Mar 2026), filed 14 Jul 2026. Document · Filing index

2 amended annual reports are listed on EDGAR.

Quarterly reports (10-Q)

Labelled by the quarter's period end.

Recent events (8-K)

  • Material agreement; New financial obligation; Unregistered sale of equity; Director/officer change8-K
  • Unregistered sale of equity8-K
  • Material agreement; New financial obligation8-K
  • Material agreement; New financial obligation8-K
  • Material agreement; New financial obligation; Unregistered sale of equity8-K

Proxy statements (DEF 14A)

Source: SEC EDGAR, checked 16 Nov 2026. All filings on SEC EDGAR

Latest News

Top Premarket Decliners MT Newswires · Nov 2, 2026 Nordicus Partners Corporation Announces Uplisting to The Nasdaq Capital Market GlobeNewswire · Oct 29, 2026 Nordicus Partners Corporation Appoints Elizabeth Addonizio to Its Board of Directors GlobeNewswire · Sep 2, 2026

About Nordicus Partners Corporation

Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines. In addition to its core operations, Nordicus offers an array of corporate finance and advisory services. These include aiding in business and market expansion, formulating strategic growth plans, identifying and acquiring talent, fostering key partnerships, facilitating capital raising efforts, and orchestrating company acquisitions or sales. The organization, which was established in 1993 and is headquartered in Beverly Hills, California, rebranded as Nordicus Partners Corporation in May 2023, having previously been known as EKIMAS Corporation.

Nordicus Partners Corporation is headquartered in US.

Nordicus Partners Corporation (NORD) stock trades at $2.57 with a market capitalization of $49.97M. The stock is valued at a negative price-to-earnings (P/E) ratio of -8.63, reflecting a net loss over the last twelve months, price-to-book of 0.73, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.48 and $5.15, and currently trades 50.1% below its 52-week high.

On profitability, Nordicus Partners Corporation generates a return on equity (ROE) of -7.95% (negative, reflecting a net loss), return on capital employed of -6.10%.

Official website: nordicuspartners.com

Nordicus Partners Corporation by the numbers, 2016–2025

Between 2016 and 2025 Nordicus Partners Corporation reported revenue of $2.0M falling to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. The net loss widened from −$1.0M in 2016 to −$4.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit −$5.0M.

Borrowings fell from $2.0M to $0, cash on hand is $0, cash from operations was −$4.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -6048.7% over five years, and was -6.3% in the most recent year.

The share price itself has compounded at -30.9% a year over five years, -33.5% over three, -51.9% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Nordicus Partners Corporation (NORD) — frequently asked questions

What is Nordicus Partners Corporation (NORD) stock price today?

Nordicus Partners Corporation (NORD) is currently trading at $2.57, up 2.39% today.

What is NORD P/E ratio?

Nordicus Partners Corporation's P/E ratio is -8.63. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is NORD return on equity (ROE)?

Nordicus Partners Corporation's return on equity (ROE) is -7.95%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Nordicus Partners Corporation's market cap?

Nordicus Partners Corporation has a market capitalization of $49.97M.

Does NORD pay a dividend?

Nordicus Partners Corporation is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does NORD carry?

Nordicus Partners Corporation has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is NORD's profit margin?

Nordicus Partners Corporation reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is NORD in?

Nordicus Partners Corporation is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is NORD listed on?

Nordicus Partners Corporation trades on OTC under the ticker NORD.

What is NORD's 52-week range?

Over the last year Nordicus Partners Corporation has traded between $1.48 and $5.15.

Related Healthcare Stocks

VRTX Vertex Pharmaceuticals Incorporated $534.85 -0.70% REGN Regeneron Pharmaceuticals, Inc. $954.06 -0.15% MRNA Moderna, Inc. $215.27 -3.63% RVMD Revolution Medicines, Inc. $168.19 -2.38% ROIV Roivant Sciences Ltd. $39.35 -0.46% INSM Insmed Incorporated $124.24 +2.55% UTHR United Therapeutics Corporation $585.89 -0.89% INCY Incyte Corporation $120.77 -0.17% ALNY Alnylam Pharmaceuticals, Inc. $161.68 -2.03% ASND Ascendis Pharma A/S - Ordinary Share $272.12 -1.19% EXEL Exelixis, Inc. $67.81 -1.73% NBIX Neurocrine Biosciences, Inc. $167.08 -0.19%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens NORD currently matches

On the figures above, Nordicus Partners Corporation passes the filters for 3 of our ready-made screens, among them Penny Stocks, Debt Free Stocks Under $100, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny StocksDebt Free Stocks Under $100Nano Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.